Atrial natriuretic peptide: A molecular target of novel therapeutic approaches to cardio-metabolic disease

Valentina Cannone, Aderville Cabassi, Riccardo Volpi, John C Jr. Burnett

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Atrial natriuretic peptide (ANP) is a cardiac hormone with pleiotropic cardiovascular and metabolic properties including vasodilation, natriuresis and suppression of the renin-angiotensin-aldosterone system. Moreover, ANP induces lipolysis, lipid oxidation, adipocyte browning and ameliorates insulin sensitivity. Studies on ANP genetic variants revealed that subjects with higher ANP plasma levels have lower cardio-metabolic risk. In vivo and in humans, augmenting the ANP pathway has been shown to exert cardiovascular therapeutic actions while ameliorating the metabolic profile. MANP is a novel designer ANP-based peptide with greater and more sustained biological actions than ANP in animal models. Recent studies also demonstrated that MANP lowers blood pressure and inhibits aldosterone in hypertensive subjects whereas cardiometabolic properties of MANP are currently tested in an on-going clinical study in hypertension and metabolic syndrome. Evidence from in vitro, in vivo and in human studies support the concept that ANP and related pathway represent an optimal target for a comprehensive approach to cardiometabolic disease.

Original languageEnglish (US)
Article number3265
JournalInternational journal of molecular sciences
Volume20
Issue number13
DOIs
StatePublished - Jul 1 2019

Fingerprint

metabolic diseases
Metabolic Diseases
Atrial Natriuretic Factor
peptides
aldosterone
Therapeutics
Aldosterone
renin
vasodilation
angiotensins
Natriuresis
Metabolome
hypertension
peptide A
Natriuretic Peptides
Lipolysis
blood pressure
Insulin
Hormones
Blood pressure

Keywords

  • Atrial natriuretic peptide
  • Cardiometabolic disease
  • cGMP
  • Guanylyl cyclase receptor A
  • Heart failure
  • Hypertension
  • Metabolic syndrome
  • Natriuretic peptides
  • Obesity

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Atrial natriuretic peptide : A molecular target of novel therapeutic approaches to cardio-metabolic disease. / Cannone, Valentina; Cabassi, Aderville; Volpi, Riccardo; Burnett, John C Jr.

In: International journal of molecular sciences, Vol. 20, No. 13, 3265, 01.07.2019.

Research output: Contribution to journalReview article

@article{2423317f70e946cdb43cd9c21ce2d886,
title = "Atrial natriuretic peptide: A molecular target of novel therapeutic approaches to cardio-metabolic disease",
abstract = "Atrial natriuretic peptide (ANP) is a cardiac hormone with pleiotropic cardiovascular and metabolic properties including vasodilation, natriuresis and suppression of the renin-angiotensin-aldosterone system. Moreover, ANP induces lipolysis, lipid oxidation, adipocyte browning and ameliorates insulin sensitivity. Studies on ANP genetic variants revealed that subjects with higher ANP plasma levels have lower cardio-metabolic risk. In vivo and in humans, augmenting the ANP pathway has been shown to exert cardiovascular therapeutic actions while ameliorating the metabolic profile. MANP is a novel designer ANP-based peptide with greater and more sustained biological actions than ANP in animal models. Recent studies also demonstrated that MANP lowers blood pressure and inhibits aldosterone in hypertensive subjects whereas cardiometabolic properties of MANP are currently tested in an on-going clinical study in hypertension and metabolic syndrome. Evidence from in vitro, in vivo and in human studies support the concept that ANP and related pathway represent an optimal target for a comprehensive approach to cardiometabolic disease.",
keywords = "Atrial natriuretic peptide, Cardiometabolic disease, cGMP, Guanylyl cyclase receptor A, Heart failure, Hypertension, Metabolic syndrome, Natriuretic peptides, Obesity",
author = "Valentina Cannone and Aderville Cabassi and Riccardo Volpi and Burnett, {John C Jr.}",
year = "2019",
month = "7",
day = "1",
doi = "10.3390/ijms20133265",
language = "English (US)",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "13",

}

TY - JOUR

T1 - Atrial natriuretic peptide

T2 - A molecular target of novel therapeutic approaches to cardio-metabolic disease

AU - Cannone, Valentina

AU - Cabassi, Aderville

AU - Volpi, Riccardo

AU - Burnett, John C Jr.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Atrial natriuretic peptide (ANP) is a cardiac hormone with pleiotropic cardiovascular and metabolic properties including vasodilation, natriuresis and suppression of the renin-angiotensin-aldosterone system. Moreover, ANP induces lipolysis, lipid oxidation, adipocyte browning and ameliorates insulin sensitivity. Studies on ANP genetic variants revealed that subjects with higher ANP plasma levels have lower cardio-metabolic risk. In vivo and in humans, augmenting the ANP pathway has been shown to exert cardiovascular therapeutic actions while ameliorating the metabolic profile. MANP is a novel designer ANP-based peptide with greater and more sustained biological actions than ANP in animal models. Recent studies also demonstrated that MANP lowers blood pressure and inhibits aldosterone in hypertensive subjects whereas cardiometabolic properties of MANP are currently tested in an on-going clinical study in hypertension and metabolic syndrome. Evidence from in vitro, in vivo and in human studies support the concept that ANP and related pathway represent an optimal target for a comprehensive approach to cardiometabolic disease.

AB - Atrial natriuretic peptide (ANP) is a cardiac hormone with pleiotropic cardiovascular and metabolic properties including vasodilation, natriuresis and suppression of the renin-angiotensin-aldosterone system. Moreover, ANP induces lipolysis, lipid oxidation, adipocyte browning and ameliorates insulin sensitivity. Studies on ANP genetic variants revealed that subjects with higher ANP plasma levels have lower cardio-metabolic risk. In vivo and in humans, augmenting the ANP pathway has been shown to exert cardiovascular therapeutic actions while ameliorating the metabolic profile. MANP is a novel designer ANP-based peptide with greater and more sustained biological actions than ANP in animal models. Recent studies also demonstrated that MANP lowers blood pressure and inhibits aldosterone in hypertensive subjects whereas cardiometabolic properties of MANP are currently tested in an on-going clinical study in hypertension and metabolic syndrome. Evidence from in vitro, in vivo and in human studies support the concept that ANP and related pathway represent an optimal target for a comprehensive approach to cardiometabolic disease.

KW - Atrial natriuretic peptide

KW - Cardiometabolic disease

KW - cGMP

KW - Guanylyl cyclase receptor A

KW - Heart failure

KW - Hypertension

KW - Metabolic syndrome

KW - Natriuretic peptides

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=85068704194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068704194&partnerID=8YFLogxK

U2 - 10.3390/ijms20133265

DO - 10.3390/ijms20133265

M3 - Review article

C2 - 31269783

AN - SCOPUS:85068704194

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 13

M1 - 3265

ER -